Streetbeat News

Regulatory

CRIS

The FDA has lifted the partial clinical hold on Curis' TakeAim Leukemia Study, with the recommended phase 2 dose (RP2D) established at 300 mg twice daily. This could potentially accelerate the development and approval process for Curis' leukemia treatment.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 12:02 pm

ASLN

ASLAN Pharmaceuticals announced that its 600mg Eblasakimab, dosed once every four weeks in the TREK-AD study, met the primary endpoint with statistical significance.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 11:57 am

LLY

The New England Journal of Medicine has published detailed results from the BRUIN Phase 1/2 trial evaluating the efficacy and safety of pirtobrutinib, a drug under investigation by Eli Lilly. The drug, a non-covalent Bruton's tyrosine kinase inhibitor, is being tested in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were previously treated with a BTK inhibitor.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 11:47 am

AMZN

GOOG

GOOGL

Google, a subsidiary of Alphabet Inc, has criticized India's antitrust body for allegedly favoring Amazon. The antitrust body demanded changes to Google's business model and fined the company $163 million. Google has appealed to India's Supreme Court to overturn the order. Amazon has complained about difficulties in developing a modified Android system due to Google's restrictions.

Portfolio Pulse from Anusuya Lahiri

July 06, 2023 | 11:47 am

LILM

Lilium has successfully completed the fourth and final Design Organization Approval (DOA) audit by the European Union Aviation Safety Agency (EASA). This is a key milestone in Lilium's progress towards becoming an EASA DOA holder, a requirement for aircraft manufacturers.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 11:32 am

TSLA

The National Highway Traffic Safety Administration (NHTSA) has sent a letter to Tesla, demanding updates to questions it had asked in August 2022. The agency has set a deadline of July 19 for Tesla to respond.

Portfolio Pulse from Charles Gross

July 06, 2023 | 11:21 am

BTCUSD

In 2017, Saudi billionaire investor Prince Alwaleed bin Talal predicted that Bitcoin would 'implode' due to lack of regulation and oversight. However, since his prediction, Bitcoin's value has surged significantly. If an investor had invested $100 in Bitcoin on the day of Alwaleed's prediction, their investment would now be worth $521.

Portfolio Pulse from Mehab Qureshi

July 06, 2023 | 11:07 am

GDTC

CytoMed Therapeutics Limited (NASDAQ:GDTC), a Singapore-based biopharmaceutical company, has been granted a patent by the US Patent and Trademark Office for its CAR-gamma delta T cell technology, which it has exclusively licensed from A*STAR.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 11:03 am

KZIA

Kazia Therapeutics has announced that its lead program, paxalisib, has been awarded Fast Track Designation by the FDA for the treatment of solid tumor brain metastases. This designation will expedite the review of the drug, potentially leading to quicker market access.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 11:02 am

NNVC

NanoViricides has announced that the clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily. The trial will continue into Part 1b if there are no serious adverse events following safety and tolerability evaluation in healthy persons for a single escalating dose of NV-CoV-2 Oral Syrup or NV-CoV-2 Oral Gummies in the Part 1a.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 10:46 am